SK3 Group, Inc.

SK3 Group, Inc. provides management advisory, licensing, and marketing services for medical marijuana collectives in California. It licenses various products for marketing and sale, including the YAK line of medical marijuana edibles; Canna-Loz, a delivery system for large doses of phyto-cannabinoids; Yeti, a pre-roll for pain relief; and Dharmanol, a proprietary technology that extracts, stabilizes, and preserves the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. The company was formerly known as CTT International Distributors, Inc. and changed its name to SK3 Group, Inc. in May 2007. The company was founded in 2000 and is headquartered in Los Angeles, California. SK3 Group, Inc. is a subsidiary of Healthcare of Today, Inc.

SK3 Group, Inc. trades as SKTO on OTC. The company is classified in Consumer Cyclical / Specialty Retail and reports in USD.

The current profile places the business in Specialty Retail. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

SK3 Group, Inc. can be compared against peers such as Alternative Energy Partners, Inc., Anything Technologies Media, Inc., Creative Edge Nutrition, Inc., FusionPharm, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $3,020, beta of -5.45, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

SKTO currently shows total debt of N/A and beta of -5.45. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.sk3group.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.